Mark G. Bandyk, M.D., M.P.H., M.S.

Mark G. Bandyk M.D., M.P.H., M.S.

Associate Professor

Department: Department of Urology
Business Phone: (904) 244-7340
Business Email:

About Mark G. Bandyk

Dr. Bandyk is a urologic oncologist with a special interest in bladder cancer. He is an expert in robotic and open surgery.

Board Certifications

  • Urology

Clinical Profile

  • Urology


Diagnostic accuracy of vesical imaging-reporting and data system (VI-RADS) in suspected muscle invasive bladder cancer: A systematic review and diagnostic meta-analysis.
Urologic oncology.40(2):45-55[DOI] 10.1016/j.urolonc.2021.11.008.[PMID] 34895996.
The Geriatric Nutritional Risk Index Predicts Postoperative Outcomes in Bladder Cancer: A Propensity Score-Matched Analysis.
The Journal of urology.207(4):797-804[DOI] 10.1097/JU.0000000000002342.[PMID] 34854753.
An Indirect Comparison of Newer Minimally Invasive Treatments for Benign Prostatic Hyperplasia: A Network Meta-Analysis Model.
Journal of endourology.35(4):409-416[DOI] 10.1089/end.2020.0739.[PMID] 32962442.
Intracorporeal versus extracorporeal urinary diversion following robot-assisted radical cystectomy: a meta-analysis, cumulative analysis, and systematic review.
Journal of robotic surgery.15(3):321-333[DOI] 10.1007/s11701-020-01174-4.[PMID] 33222043.
MRI and CT bladder segmentation from classical to deep learning based approaches: Current limitations and lessons.
Computers in biology and medicine.134():104472-[DOI] 10.1016/j.compbiomed.2021.104472.[PMID] 34023696.
Pathology grade influences competing mortality risks in elderly men with prostate cancer.
Urologic oncology.39(8):493.e1-493.e7[DOI] 10.1016/j.urolonc.2020.12.004.[PMID] 33353870.
Variability of the Positive Predictive Value of PI-RADS for Prostate MRI across 26 Centers: What about the Negatives?
Radiology.298(1):E57-[DOI] 10.1148/radiol.2020202870.[PMID] 33141006.
A Systematic Review and Meta-Analysis of Methods Used to Reduce Infectious Complications Following Transrectal Prostate Biopsy.
Urology.144():21-27[DOI] 10.1016/j.urology.2020.06.005.[PMID] 32569659.
Comparative efficacy of apalutamide darolutamide and enzalutamide for treatment of non-metastatic castrate-resistant prostate cancer: A systematic review and network meta-analysis.
Urologic oncology.38(11):826-834[DOI] 10.1016/j.urolonc.2020.03.022.[PMID] 32605736.
Percutaneous ablative cryoimmunotherapy for micrometastaic abscopal effect: No complications.
Cryobiology.82():22-26[DOI] 10.1016/j.cryobiol.2018.04.013.[PMID] 29680230.
Rectal Culture and Sensitivity Analysis for Reducing Sepsis Risk After Fiducial Marker Placement.
American journal of clinical oncology.41(12):1243-1245[DOI] 10.1097/COC.0000000000000454.[PMID] 29727310.
Decipher test impacts decision making among patients considering adjuvant and salvage treatment after radical prostatectomy: Interim results from the Multicenter Prospective PRO-IMPACT study.
Cancer.123(15):2850-2859[DOI] 10.1002/cncr.30665.[PMID] 28422278.
Characterization of the products of a gene expressed during androgen-programmed cell death and their potential use as a marker of urogenital injury.
The Journal of urology.143(2):407-13[DOI] .[PMID] 2299741.

Office Information

Academic Office
3rd Floor, Faculty Clinic
653 West 8th Street, FC12
Jacksonville, FL 32209
(904) 244-7340
Administrative Manager
Sammie Adkins
(904) 244-7340


Medical Degree
1983 · George Washington University, Washington, DC, USA
Tumor Immunology Fellowship
1986 · Salk Institute, La Jolla, CA, USA
Surgery Residency
1987 · University of California (San Francisco) School of Medicine, San Francisco, CA, USA
Urology Residency
1990 · Columbia University, New York, NY, USA
Urologic Oncology Fellowship
1993 · University of Texas, Houston, TX, USA